Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling (Q37148218)
Jump to navigation
Jump to search
scientific article published on 08 August 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling |
scientific article published on 08 August 2013 |
Statements
1 reference
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling (English)
1 reference
T-H Lin
1 reference
K Izumi
1 reference
S O Lee
1 reference
W-J Lin
1 reference
S Yeh
1 reference
C Chang
1 reference
8 August 2013
1 reference
1 reference
e764
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference